Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

8-year Analysis of the Prevalence of Lymph Nodes Metastasis, Oncologic and Pregnancy Outcomes in Apparent Early-Stage Malignant Ovarian Germ Cell Tumors

  • Chatchotikawong, Usanee (Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Faculty of Medicine, Siriraj Hospital, Mahidol University) ;
  • Ruengkhachorn, Irene (Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Faculty of Medicine, Siriraj Hospital, Mahidol University) ;
  • Leelaphatanadit, Chairat (Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Faculty of Medicine, Siriraj Hospital, Mahidol University) ;
  • Phithakwatchara, Nisarat (Maternal Fetal Medicine Division, Department of Obstetrics and Gynecology, Faculty of Medicine, Siriraj Hospital, Mahidol University)
  • Published : 2015.03.09
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To determine the rate of lymph node metastasis, oncologic and pregnancy outcomes in apparent early-stage malignant ovarian germ cell tumor (MOGCT). Materials and Methods: Medical records of apparent early-stage MOGCT patients undergoing primary surgical treatment at Siriraj Hospital, Bangkok, Thailand, between January 2006 and December 2013, were retrospectively reviewed. Results: Thirty-eight patients had apparent stage I-II MOGCT. The mean age was $22.1{\pm}7.7years$ (median, 20.8 years; range, 7.7-35.6 years). The mean tumor size was $17.8{\pm}6.5cm$ with a median of 20 (range 4-30) cm. Three most common histopathologies were dysgerminoma (12 patients, 31.6%), immature teratoma (12 patients, 31.6%), and endodermal sinus tumor (6 patients, 15.8%). Twenty-seven of 38 patients underwent lymphadenectomy; 13 patients (48.2%) were stage IA and 8 patients (29.6%) were stage IC. The rate of retroperitoneal nodes metastasis was 7.4% (2/27 patients). At 26.1 months of median follow-up time (range 1.9-88.5 months), 9 patients retained fertility functions, with uneventful pregnancies in 3 of these. Only one patient (2.6%) had progression of disease at 4.9 months after surgery. The 5-year survival rate was 97.4%. Conclusion: As the rate of pelvic or para-aortic node metastasis in MOGCT is considerable, lymphadenectomy should be incorporated in surgical staging procedures.

Keywords

References

  1. Bilici A, Inanc M, Ulas A, et al (2014). Clinical and pathologic features of patients with rare ovarian tumors: multi-center review of 167 patients by the Anatolian Society of Medical Oncology. Asian Pac J Cancer Prev, 15, 6493-9.
  2. Colombo N, Peiretti M, Garbi A, et al (2012). Non-epithelial ovarian cancer: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 23, 20-6.
  3. Dimopoulos MA, Papadimitriou C, Hamilos G, et al (2004). Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. Gynecol Oncol, 95, 695-700. https://doi.org/10.1016/j.ygyno.2004.08.018
  4. Gershenson DM (2007). Management of ovarian germ cell tumors. J Clin Oncol, 25, 2938-43. https://doi.org/10.1200/JCO.2007.10.8738
  5. Kleppe M, Amkreutz LC, Van Gorp T, et al (2014). Lymph-node metastasis in stage I and II sex cord stromal and malignant germ cell tumours of the ovary: a systematic review. Gynecol Oncol, 133, 124-7.
  6. Kumar S, Shah JP, Bryant CS, et al (2008). The prevalence and prognostic impact of lymph node metastasis in malignant germ cell tumors of the ovary. Gynecol Oncol, 110, 125-32. https://doi.org/10.1016/j.ygyno.2008.04.022
  7. Lai CH, Chang TC, Hsueh S, et al (2005). Outcome and prognostic factors in ovarian germ cell malignancies. Gynecol Oncol, 96, 784-91. https://doi.org/10.1016/j.ygyno.2004.11.027
  8. Low JJ, Ilancheran A, Ng JS (2012). Malignant ovarian germ-cell tumours. Best Pract Res Clin Obstet Gynaecol, 26, 347-55. https://doi.org/10.1016/j.bpobgyn.2012.01.002
  9. Liu Q, Ding X, Yang J, et al (2013). The significance of comprehensive staging surgery in malignant ovarian germ cell tumors. Gynecol Oncol, 131, 551-4. https://doi.org/10.1016/j.ygyno.2013.08.016
  10. Mahdi H, Swensen RE, Hanna R, et al (2011). Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary. Br J Cancer, 9, 493-7.
  11. Murugaesu N, Schmid P, Dancey G, et al (2006). Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol, 24, 4862-6. https://doi.org/10.1200/JCO.2006.06.2489
  12. Neeyalavira V, Suprasert P (2014). Outcomes of malignant treated in Chiang Mai University Hospital over a nine year period. Asian Pac J Cancer Prev, 15, 4909-13. https://doi.org/10.7314/APJCP.2014.15.12.4909
  13. Patterson DM, Rustin GJ (2006). Controversies in the management of germ cell tumours of the ovary. Curr Opin Oncol, 18, 500-6. https://doi.org/10.1097/01.cco.0000239891.44031.38
  14. Patterson DM, Murugaesu N, Holden L, Seckl MJ, Rustin GJ (2008). A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites. Int J Gynecol Cancer, 18, 43-50. https://doi.org/10.1111/j.1525-1438.2007.00969.x